Gongwin Biopharm Holdings Co., Ltd. (TPEX: 6617)
Taiwan
· Delayed Price · Currency is TWD 120.00
-6.00 (-4.76%)
Sep 10, 2024, 1:30 PM CST
Gongwin Biopharm Holdings Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -110.05 | -101.18 | -292.13 | -121.58 | -93.07 | -109.82 | Upgrade
|
| Depreciation & Amortization | 12.45 | 13.33 | 13.39 | 12.96 | 12.53 | 12.05 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | - | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -0.74 | -4.68 | -0.98 | Upgrade
|
| Stock-Based Compensation | 9.36 | - | 29.29 | 0.57 | 11.02 | 10.75 | Upgrade
|
| Other Operating Activities | 11.79 | -1.02 | -4.83 | 4.36 | -8.16 | -7.45 | Upgrade
|
| Change in Accounts Receivable | -13.27 | -10.58 | - | - | - | 0.07 | Upgrade
|
| Change in Inventory | -0.04 | -11.72 | -0.21 | - | - | - | Upgrade
|
| Change in Accounts Payable | -10.11 | -2.86 | 11.72 | 2.83 | -0.79 | -7.3 | Upgrade
|
| Change in Unearned Revenue | 2.6 | 2.6 | 12.31 | 3.25 | - | 1.95 | Upgrade
|
| Change in Other Net Operating Assets | 10.32 | 0.63 | -1.72 | 2.84 | -4.11 | -0.81 | Upgrade
|
| Operating Cash Flow | -82.36 | -110.8 | -232.2 | -95.51 | -87.26 | -101.55 | Upgrade
|
| Capital Expenditures | -199.84 | -0.91 | -7.34 | -123.01 | -30.14 | -5.91 | Upgrade
|
| Sale (Purchase) of Intangibles | -0.08 | -0.22 | - | - | - | - | Upgrade
|
| Investment in Securities | 282.04 | -279.84 | -194.5 | -123.76 | 107.18 | 185.58 | Upgrade
|
| Other Investing Activities | 0.88 | - | -0.17 | 0.36 | - | -0.02 | Upgrade
|
| Investing Cash Flow | 82.99 | -280.97 | -202.01 | -246.42 | 77.05 | 179.66 | Upgrade
|
| Short-Term Debt Issued | - | 119.16 | 50.29 | 144.56 | 8.38 | 228.03 | Upgrade
|
| Total Debt Issued | 270.78 | 119.16 | 50.29 | 144.56 | 8.38 | 228.03 | Upgrade
|
| Short-Term Debt Repaid | - | -181.51 | -30 | -60.73 | - | -287.54 | Upgrade
|
| Long-Term Debt Repaid | - | -5.04 | -4.9 | -4.73 | -5.78 | -24.68 | Upgrade
|
| Total Debt Repaid | -186.1 | -186.55 | -34.9 | -65.46 | -5.78 | -312.22 | Upgrade
|
| Net Debt Issued (Repaid) | 84.67 | -67.39 | 15.4 | 79.11 | 2.6 | -84.19 | Upgrade
|
| Issuance of Common Stock | 1,989 | 11.95 | 575.42 | 22.66 | 538.83 | 1.2 | Upgrade
|
| Other Financing Activities | 35.42 | 43.34 | 13.24 | 0 | - | 24.12 | Upgrade
|
| Financing Cash Flow | 2,109 | -12.1 | 604.05 | 101.77 | 541.43 | -58.87 | Upgrade
|
| Foreign Exchange Rate Adjustments | 21.16 | 5.94 | 47.55 | -12.96 | -13.68 | -2.01 | Upgrade
|
| Net Cash Flow | 2,131 | -397.92 | 217.39 | -253.11 | 517.54 | 17.23 | Upgrade
|
| Free Cash Flow | -282.2 | -111.7 | -239.54 | -218.52 | -117.4 | -107.45 | Upgrade
|
| Free Cash Flow Margin | -890.01% | -590.55% | -20956.69% | -19118.11% | -14093.16% | -43327.42% | Upgrade
|
| Free Cash Flow Per Share | -2.48 | -0.99 | -2.16 | -1.99 | -1.12 | -1.04 | Upgrade
|
| Cash Interest Paid | 3.11 | 7.19 | 3.07 | 1.08 | 0.36 | 1.63 | Upgrade
|
| Cash Income Tax Paid | 0.05 | 0.04 | -0.05 | -0.16 | -0.07 | 0.21 | Upgrade
|
| Levered Free Cash Flow | -192.82 | -23.45 | -255.26 | -239.95 | -94.65 | -33.37 | Upgrade
|
| Unlevered Free Cash Flow | -190.54 | -18.96 | -253.27 | -239.21 | -94.33 | -32.49 | Upgrade
|
| Change in Net Working Capital | -73.75 | -52.17 | 125.68 | 54.21 | 14.4 | -31.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.